Send me real-time posts from this site at my email
Motley Fool

Why Radius Health Stock Is Getting Pummeled Today

What happened

The stock of Radius Health (NASDAQ: RDUS) is tumbling today after the company presented follow-up data for its experimental breast cancer treatment. Investors disappointed with the biopharmaceutical company's update pushed the stock 44.3% lower as of 12:44 p.m. ET on Wednesday.

So what

Back in October, Radius stock shot up when the company told investors its elacestrant, a potential first-in-class selective estrogen receptor degrader (SERD), significantly reduced the risk of disease progression for advanced-stage breast cancer patients during the phase 3 Emerald trial.

Image source: Getty Images.

Investors were hoping a strong benefit was measured for all trial participants and not only patients with tumors that harbor estrogen receptor 1 (ESR1) mutations. The stock is tanking today because it looks like elacestrant's indication, if approved, will be limited to the smaller subgroup of ESR1-positive patients.

Now what

Treatment with elacestrant reduced patients' risk of disease progression by 30% compared to trial participants randomized to receive standard care. Among just the ESR1-positive patients, elacestrant reduced the risk of disease progression by 45% versus standard care.

At recent prices, Radius has a low $388 million market cap. That's less than half as much as the company was worth a couple of months ago. Even if we assume elacestrant will be limited to the ESR1-positive population, it looks like the market is underestimating its future sales potential.

10 stocks we like better than Radius Health
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Radius Health wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of November 10, 2021

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue